- Khiron Life Sciences establishes early mover position to build
its brand and product offering in the United Kingdom's nascent medical cannabis
market
- Project Twenty21 will study medical cannabis's therapeutic
effects on 20,000 patients - and build largest ever evidence base
for UK National Health Service (NHS) provision of these
medicines
- Real-world data registry will document patient outcomes in
those prescribed medical cannabis and support health authority
applications
- Project welcomed by The Royal College of Psychiatrists, peers,
The British Pain Society, United Patients Alliance and leading
campaigners, including Hannah Deacon
- whose high profile case led to her son, Alfie Deacon, being one of the few prescribed
medical cannabis for his intractable epilepsy
- Alongside epilepsy, the project will address Chronic Pain,
Multiple Sclerosis, Post Traumatic Stress Disorder (PTSD), and
other chronic conditions
TORONTO, Nov. 19, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America, announced today that it will be
the exclusive Latin American provider of cannabis medicines to
Project Twenty21 in the United
Kingdom.
Project Twenty21, Europe's
first and biggest national medical cannabis registry, was launched
on November 7, 2019 at the Royal
College of Psychiatrists in London. The project will enrol 20,000 patients
by the end of 2021, creating the largest body of evidence for the
efficacy of medical cannabis, with an aim to then convince UK
policy makers that medical cannabis should be as widely available,
and affordable, as other approved medicines for patients who would
benefit from them.
It will also aim to support prescribers across the country to
feel confident in providing medical cannabis to such patients,
while helping to build a case for NHS funding in seven key
identified conditions. These conditions include Chronic Pain,
Epilepsy, Multiple Sclerosis, Post Traumatic Stress Disorder
(PTSD), Tourette's Syndrome, Anxiety Disorder or those who are
dealing with the harm of substance misuse.
Leading the project, Professor David
Nutt from the UK's leading independent scientific body Drug
Science commented: "Medical cannabis is still out of reach for far
too many. Patients are left untreated, in significant debt from the
cost of private prescriptions, or criminalized as they are forced
to turn to the illicit market. They don't deserve any of this, and
the situation with prescribing desperately needs to change."
The study will use real-world data to document the
effectiveness, safety, quality of life, and patient reported
outcomes in those prescribed medical cannabis for these conditions.
It will not be a randomised control trial (where some would receive
placebo), and all 20,000 participants will receive medical cannabis
from participating providers at an affordable cost, subsidised in
part by the cannabis providers, including Khiron, and by Drug
Science itself. Project Twenty21 has the support of The Royal
College of Psychiatrists, The British Pain Society, the United
Patients Alliance, patients, peers and medical cannabis
campaigners.
The participation of Khiron in Project Twenty21 in the
United Kingdom further cements the
Company's focused regional strategy of entering and capturing
market share in the region's estimated €115.7 Billion medical
cannabis market by 2028 (Prohibition Partners).
Management Commentary
Tejinder
Virk, President of Khiron Europe, commented, "We are excited
to have this opportunity to participate in Project Twenty21 and
help improve access to cannabis medicines in the UK. According to
the Centre for Medicinal Cannabis, it is estimated that 1.4 million
people in the UK are using illicit or 'street cannabis' to treat
the symptoms of chronic conditions. Once available, patients will
benefit from Khiron's high quality product offering and our
inherent cost advantages. In advance of a more liberalized medical
cannabis market in the UK, the study provides prescribers and
patients an opportunity to get early familiarity with Khiron's
brand and product offering."
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is positioned to be the dominant integrated cannabis company
in Latin America. Khiron has core
operations in Latin America and is
fully licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both tetrahydrocannabinol (THC) and cannabidiol (CBD)
medical cannabis. The company delivers best in class regulatory
compliance, has the first approved set of CBD cosmetic products on
shelf in Colombia, and is currently facilitating testing to
meet and surpass all license requirements for commercial cannabis
derived products.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Cautionary Notes
Forward-Looking Statements
This press release
may contain certain "forward-looking information" and
"forward-looking statements" within the meaning of applicable
securities legislation. All information contained herein that is
not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Further information in respect of the Company can be found
at www.khiron.ca.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-to-be-exclusive-latin-american-provider-to-project-twenty21--europes-largest-medical-cannabis-study-with-20-000-patients-300960595.html
SOURCE Khiron Life Sciences Corp.